Skip to main content
Real-world evidence for COSELA
Navbar Image
Real-world evidence for COSELA
This site is intended only for US healthcare professionals.

Real-world evidence for COSELA

No cases of thrombocytopenia or platelet transfuSions with COSELA in a real-world study1

  • Fewer platelet-related events from chemotherapy in patients receiving COSELA in a real-world study, including1:
    • Grade 3/4 thrombocytopenia (secondary endpoint)
    • Platelet transfusions (secondary endpoint)
  • Although permanent discontinuation was not specifically mentioned in the publication, permanent discontinuation due to an adverse reaction in patients receiving COSELA in the clinical trials occurred in 9% of patients and included thrombocytopenia, cerebrovascular accident, and ischemic stroke (<1% each)
See the Study Design
a
Of the 62 patients identified who received etoposide/carboplatin/atezolizumab + COSELA, 34 met the inclusion criteria for review. Inconsistent COSELA utilization from cycle 2 and onward was the most common reason for exclusion (n=11). Likewise, 44 patients in the etoposide/carboplatin/atezolizumab cohort were included for review from an initial list of 65 patients. Lost to follow-up (n=7) and carboplatin area under the curve <3.5 with cycle 1 (n=6) were the most common reasons for exclusion.1
Real-world evidence is observational and may be subject to limitations, including lack of randomization.